Hoffmann-La Roche

CO40016

NCT03337724

JCP031

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-, PIK3CA, AKT, PTEN

Investigational

Product

Ipatasertib

Treatment Arms

o Experimental: Ipatasertib + Paclitaxel

o Placebo + Paclitaxel